Mangrove Therapeutics
June 22, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Inflammation
Mangrove Therapeutics is developing first-in-class therapies targeting a novel RNA-mediated master regulator of inflammation, addressing a key gap in polygenic disease biology. While over 95% of patients with inflammatory conditions carry polygenic risk that is not mechanistically actionable with current therapeutic approaches, Mangrove identified a causal pathway validated by human genetics, enabling precise patient stratification and broad therapeutic impact. The company combines AI-informed genetic diagnostics with small molecule and siRNA approaches to modulate the causal pathway which mediates immune signaling and inflammation. Utilizing validated primary assays and disease mechanisms, Mangrove aims to unlock treatments across multiple high-value inflammatory indications.
Company HQ City:
Stanford
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2025
CEO
Benjamin Chen
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}